Advertisement
HIMS vs SKIN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIMS is a Hold and SKIN is a Buy.
HIMS's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for HIMS moved out of oversold territory on November 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 21 of the 24 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 71 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for HIMS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (6.379). P/E Ratio (-41.935) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
SKIN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SKIN turned positive on November 03, 2026. Looking at past instances where SKIN's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SKIN as a result. In 76 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
SKIN moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SKIN crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +61.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKIN advanced for three days, in 191 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKIN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SKIN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SKIN entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.793) is normal, around the industry mean (21.731). SKIN has a moderately low P/E Ratio (-68.304) as compared to the industry average of (16.288). Projected Growth (PEG Ratio) (0.858) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.032) among similar stocks. P/S Ratio (0.302) is also within normal values, averaging (1.902).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SKIN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKIN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
HIMS | SKIN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 85 | 38 | |
P/E GROWTH RATING 1..100 | 98 | 44 | |
SEASONALITY SCORE 1..100 | 46 | 13 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SKIN's Valuation (14) in the null industry is somewhat better than the same rating for HIMS (62). This means that SKIN’s stock grew somewhat faster than HIMS’s over the last 12 months.
HIMS's Profit vs Risk Rating (83) in the null industry is in the same range as SKIN (100). This means that HIMS’s stock grew similarly to SKIN’s over the last 12 months.
HIMS's SMR Rating (97) in the null industry is in the same range as SKIN (98). This means that HIMS’s stock grew similarly to SKIN’s over the last 12 months.
SKIN's Price Growth Rating (38) in the null industry is somewhat better than the same rating for HIMS (85). This means that SKIN’s stock grew somewhat faster than HIMS’s over the last 12 months.
SKIN's P/E Growth Rating (44) in the null industry is somewhat better than the same rating for HIMS (98). This means that SKIN’s stock grew somewhat faster than HIMS’s over the last 12 months.
| HIMS | SKIN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 75% |
| Advances ODDS (%) | 9 days ago 86% | 4 days ago 79% |
| Declines ODDS (%) | 3 days ago 81% | 14 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HIMS’s FA Score shows that 0 FA rating(s) are green while SKIN’s FA Score has 1 green FA rating(s).
- HIMS’s FA Score: 0 green, 5 red.
- SKIN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HIMS’s TA Score shows that 4 TA indicator(s) are bullish while SKIN’s TA Score has 5 bullish TA indicator(s).
- HIMS’s TA Score: 4 bullish, 6 bearish.
- SKIN’s TA Score: 5 bullish, 5 bearish.
Price Growth
HIMS (@Pharmaceuticals: Generic) experienced а -21.94% price change this week, while SKIN (@Household/Personal Care) price change was +50.86% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.
The average weekly price growth across all stocks in the @Household/Personal Care industry was +8.34%. For the same industry, the average monthly price growth was +7.40%, and the average quarterly price growth was +28.26%.
Reported Earning Dates
HIMS is expected to report earnings on Mar 01, 2027.
SKIN is expected to report earnings on Mar 17, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Household/Personal Care (+8.34% weekly)Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of people’s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.
Advertisement
HIMS and
Correlation & Price change
A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To HIMS | 1D Price Change % | ||
|---|---|---|---|---|
| HIMS | 100% | +8.78% | ||
| COTY - HIMS | 31% Poorly correlated | -6.24% | ||
| HROW - HIMS | 29% Poorly correlated | -3.26% | ||
| AYTU - HIMS | 28% Poorly correlated | N/A | ||
| DERM - HIMS | 25% Poorly correlated | +0.45% | ||
| IRWD - HIMS | 25% Poorly correlated | +1.25% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| COHH | 3.05 | 0.47 | +18.45% |
| Leverage Shares 2X Long COHR Daily ETF (COHH) | |||
| PAUG | 46.75 | 0.36 | +0.78% |
| Innovator U.S. Equity Power Buffer ETF - August (PAUG) | |||
| DDIV | 45.79 | 0.32 | +0.70% |
| First Trust Dorsey Wright Momentum & Dividend ETF (DDIV) | |||
| RTH | 283.97 | -0.12 | -0.04% |
| VanEck Retail ETF (RTH) | |||
| TVE | 23.09 | -0.04 | -0.17% |
| Tennessee Valley Authority Power Bonds 1999 Series A due May 1 2029 | |||